Sanofi (SNY) posts mixed quarterly results, beating estimates for earnings while missing the same for sales. It raises its 2024 earnings growth expectations at CER.
Online availability of Sanofi's half-year financial report for 2024 Paris, July 25, 2024. Sanofi announces that its half-year financial report for the period ending June 30, 2024 is now available and
Sanofi's second-quarter profit rose 3.2% on strong demand for its blockbuster asthma drug Dupixent and better-than-expected sales of new launches, with the company now expecting a stable full-year pro
Let's look at five biotech and drug companies, AZN, ABBV, VKTX, SNY and BMY, slated to release their second-quarter 2024 results this week.
NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A ALTUVIIIO provides high-sustained factor levels wit
Today, we'll explore three stable  blue-chip stocks to buy. As the earnings season approaches, Wall Street is getting readyfor potential market volatility.
French drugmaker Sanofi plans to invest 400 million euros ($437.24 million) in its global capacity centre (GCC) in India by the end of the decade, as it aims to expand and more than double its workfor
Investors have been running on a high for the last several months as all major U.S.
Customers will start receiving shipments from July 10 with additional shipments through October to healthcare provider offices, pharmacies and other immunizers to support fall immunization campaigns.
Shares of Kymera Therapeutics (KYMR) jumped Tuesday, a day after it said partner Sanofi (SNY) agreed to extend a Phase 2 trial of its experimental drug to treat certain autoimmune skin diseases.
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering pr
Bpifrance Executive Director Jose Gonzalo said that the public investment bank is considering a potential investment in Sanofi's consumer health unit, Bloomberg News reported on Thursday.
Stock spinoffs typically don't do well initially. Unloved by shareholders of the former parent company, often misunderstood by the market and sometimes laden with debt or other baggage the parent no l
Sanofi CEO Paul Hudson joins Caroline Hyde to discuss the company's integration of AI tools in everyday operations, the impact of AI on the biopharma sector, and the company's Dupixent drug getting cl
Savvy investors must own safe haven stocks that provide stability and growth potential in an unstable economic environment. Recognizing which companies can withstand market declines becomes critical a
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE